Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

imary brain cancer.  It does not include any of the myriad other types of cancers.    

Linda Powers, CEO of Northwest Bio, commented that "We want to correct the misleading statements about patents that have been made by certain parties with a vested interest in slowing us down.  We have confirmed our analysis with patent experts at leading national law firms, and received supporting opinions from them.  We plan to continue correcting misleading statements by other parties, and we urge anyone who is interested in confirming the true facts to review the entire 8-year record of the Cedars Sinai/IMUC '090 patent application process, and the USPTO rejections.  The entire record is publicly available to all online from the USPTO." 

Powers concluded by stating that "We are justifiably confident that we do not infringe the '090 patent, and are prepared to assert all of our rights and remedies.  The '090 patent is neither a barrier nor even a speed bump in the way of our development and future commercialization of DCVax."

About Northwest Biotherapeutics

NW Bio is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis in both the US and Europe.  The Company has a broad platform technology for dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  For further information
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Milwaukee, Wis. - A cardiac surgery team led by ... a temporary total artificial heart at Aurora St. Luke's ... been among the first to introduce this new technology to ... program, in a release. , ,The Madison-area patient, who was ...
... arrangement, an area producer of ingredients for drug candidates ... , Scientific Protein Laboratories, LLC , a producer of ... has been purchased by the publicly traded buyout firm ... ,American Capital's significant capital resources will be utilized to ...
... - The United States Catholic Bishops did not waver, ... White House . , , Wisconsin Right to Life , ... of deriving stem cells from human embryos that does not destroy ... promising development. , ,While various objections still remain, could the fact ...
Cached Biology Technology:Protein lab could prosper under new owner 2There's a new dynamic in the stem cell debate 2There's a new dynamic in the stem cell debate 3There's a new dynamic in the stem cell debate 4
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
(Date:4/17/2014)... the Cell Press journal Current Biology on ... novel sex lives. The Brazilian insects, which represent four ... , are the first example of an animal with ... identified in several different animals, Neotrogla is ... also reversed," says Kazunori Yoshizawa from Hokkaido University in ...
(Date:4/17/2014)... at the University of Texas Medical Branch at ... women treated with radiation for cervical cancer should ... , The UTMB researchers, finding a high ... survivors treated with radiation, offer new recommendations that ... cancer screening about eight years after their initial ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2
... Spanish . , Contributing to the diversity ... or a few species); using examples of native flora preferably ... in the design of landscaped areas are some of the ... a low-allergy impact. That is the opinion of Paloma ...
... CA -- A link between the immune system and ... of obsolete or toxic parts may one day yield ... deadly infectious diseases. Scientists with the U.S. Department of ... discovered proteins residing in both systems that point to ...
... New York (Sept. 21, 2008) A study in ... describes the function and interaction of a critical ... These new findings reveal that blocking this molecule, called ... may be viable therapeutic strategies for the prevention and ...
Cached Biology News:Expert recommends town councils to design low-allergy impact green spaces 2Proteomics study yields clues as to how tuberculosis might be thwarting the immune system 2Proteomics study yields clues as to how tuberculosis might be thwarting the immune system 3Mitochondria could be a target for therapeutic strategy for Alzheimer's disease patients 2
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
... Antibody to Asb-2 (Ankyrin repeat and SOCS ... against synthetic peptides containing amino acids 75-93 ... spleen lysate (Imgenex Catalog No. 40149) can ... should cross react with mouse and rat ...
Biology Products: